WHO Issues Warning Over Critical Scarcity of Obesity Injections
Less than a tenth of individuals who could benefit from weight-loss injections such as Wegovy can access them, states the global health agency as it issues its first advice on the medications.
Considering over a billion people worldwide now classified as obese, it is urging more widespread and fairer availability to GLP-1 medication.
According to projections, in excess of 2,000,000,000 are projected to be living with obesity by 2030 if no action is taken.
"Our new guidance recognises that excess weight is a long-term condition that can be treated with thorough and ongoing support," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are major obstacles to broad access to the injections that can help people shift considerable body mass, notes the organization.
GLP-1 Therapy Scarcity
Even in the current best projected scenario, the supply of GLP-1 therapies would only suffice for approximately 100 million people – under 10% of those who need them, per the WHO.
The guideline encourages countries and companies to widen availability, by approaches such as licensing agreements.
A patent on semaglutide – the primary ingredient of a leading brand – is set to lapse in multiple nations in 2026.
The Way Weight-Loss Drugs Operate
The injections imitate a body's own hormone to reduce digestion speed, reduce hunger and increase satiety so people consume fewer calories.
People commonly see weight reduction after several weeks of commencing the once-weekly jabs.
Evidence indicates people may put most of the weight back on after a year of halting the medication, when their normal appetite come back.
Being overweight or obese increases your chance for experiencing medical conditions, including type 2 diabetes, heart disease, brain attack, and certain malignancies.
Excess weight impacts individuals in countries worldwide and was linked to millions of fatalities worldwide in 2024, per the health agency.
